• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Recombinant Human TNFRSF17 protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg1812

Validation Data Gallery

Product Information

Purity >90 %, SDS-PAGE
Endotoxin <1.0 EU/μg protein, LAL method
Activity 
Not tested
Expression HEK293-derived Human TNFRSF17 protein Met1-Ala54 (Accession# Q02223) with a rabbit IgG Fc tag at the C-terminus.
GeneID 608
Accession Q02223
PredictedSize 32.2 kDa
SDS-PAGE
Formulation Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

BCMA (B cell maturation antigen), also known as TNFRSF17, is 20.2-kDa type III transmembrane glycoprotein and is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes and plasma cells, which may be important for B cell development and autoimmune response. BCMA has two agonist ligands: a proliferation-inducing ligand (APRIL) and BAFF. When BCMA binds to APRIL, it transmits signals of cell survival and proliferation; when BCMA binds to BAFF, it mediates the activation of NF-kappaB and MAPK8/JNK. It has been found that the overexpression and activation of BCMA are associated with multiple myeloma (MM) in preclinical models and humans, supporting its potential utility as a therapeutic target for MM.

References:

1. Bo Yu et al (2020). J Hematol Oncol. Sep 17;13(1):125.
2. C Madry et al (1998). Int Immunol. Nov;10(11):1693-702.
3. Yu-Tzu Tai et al (2016). Blood. Jun 23;127(25):3225-36.
4. Fabrice Jardin (2022). Biomedicines. Sep 1;10(9):2153. 
5. Nina Shah et al (2020). Leukemia. Apr;34(4):985-1005.